Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Inclusion Criteria: ELIGIBILITY FOR VACCINE PREPARATION: Patients must have a diagnosis of multiple myeloma and be eligible for a Fred Hutchinson Cancer Research Center (FHCRC) treatment protocol using high dose therapy with syngeneic, allogeneic or autologous marrow or stem cell transplantation Pretransplant sera available with immunoglobulin A (IgA), immunoglobulin D (IgD), immunoglobulin E (IgE), immunoglobulin G (IgG), or immunoglobulin M (IgM) monoclonal paraprotein with a level of 1.5 grams/dl or greater identifiable on serum protein electrophoresis; eligibility for patients with pretransplant paraprotein levels of less than 1.5 gm/dl will be evaluated on an individual basis to determine whether purification of idiotype is feasible ELIGIBILITY FOR POST-TRANSPLANT IDIOTYPE VACCINATION: Successful isolation and production of an autologous idiotype vaccine from pre-BMT sera Greater than 60 days post BMT Achievement of a partial remission or greater (more than 75% reduction in serum paraprotein) for patients transplanted in relapse Stable absolute neutrophil count (ANC) > 1000 Platelet count > 50,000 not requiring transfusions or growth factors Red blood cell (RBC) supportable to hematocrit (Hct) > 25 with less than 2 units of packed red blood cell (PRBC)/week Treatment with a stable dose of Interferon is allowed Karnofsky status > 60 percent Immunosuppression: Off all corticosteroids Either off all immunosuppressive medications or on a stable/tapering dose of cyclosporin or FK506 only Exclusion Criteria: Graft-vs-host disease requiring treatment with corticosteroids Serum creatinine > 3.0 Uncontrolled infection Disease progression Presence of medical complication that in the opinion of the investigators would result in inability to tolerate the vaccination protocol Patients with a history of serious adverse reactions to GM-CSF Patients with a history of serious adverse reactions to IL-2 will not receive concurrent IL-2 administration but may receive the Id-KLH vaccine with GM-CSF